Application of tissue-specific NK and NKT cell activity for tumor immunotherapy.
Natural killer (NK) and NKT cells are a first line of defense against pathogens and transformed cells. However, dysregulation of their function can lead to autoimmune disease. A better understanding of the mechanisms controlling NK and NKT effector function should lead to the development of improved strategies for the treatment of many diseases. The site in which NK and NKT cells reside should be taken into account, because accumulating evidence suggests that the tissue microenvironment strongly influences their function. In this regard, the liver represents a unique immunologic organ in which the balance between the need for tolerance and the ability to respond rapidly to pathogens and tissue injury is tightly regulated. NK cells in the liver have augmented cytolytic activity as compared to other organs, which is consistent with a role for liver-associated NK cells in being critical effector cells for inhibiting tumor metastasis in the liver. Several studies also suggest that hepatic NKT cells have different functions than those in other organs. Whereas splenic and thymic NKT cells have been shown to suppress diabetes development, facilitate the induction of systemic tolerance and are regulated by IL-4 and other Th2 cytokines, certain subsets of NKT cells in the liver are important sources of Th1 cytokines such as Interferon gamma, and are the primary mediators of anti-tumor responses. The unique properties and roles as critical effector cells make NK and NKT cells within the liver microenvironment attractive targets of immunotherapeutic approaches that have the goal of controlling tumor metastasis in the liver.
Subleski
Jeff J
JJ
Cancer and Inflammation Program, National Cancer Institute, 1050 Boyles Street, Frederick, MD 21702, USA. jsubleski@mail.ncifcrf.gov
Wiltrout
Robert H
RH
Weiss
Jonathan M
JM
D000818:Animals; D016207:Cytokines / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007157:Immunologic Surveillance; D007167:Immunotherapy / Q000379:methods*; D007694:Killer Cells, Natural / Q000276:immunology*; D008099:Liver / Q000276:immunology* / Q000473:pathology; D008113:Liver Neoplasms / Q000556:secondary / Q000628:therapy*; D055611:Natural Killer T-Cells / Q000276:immunology*; D009362:Neoplasm Metastasis
D016207:Cytokines
J Autoimmun. 2007 Dec;29(4):206-12
17904335
J Autoimmun. 2008 May;30(3):105-7
18243658
Immunity. 2006 Mar;24(3):249-57
16546094
J Autoimmun. 2007 Dec;29(4):287-94
17826952
Cancer Res. 2001 Feb 1;61(3):884-8
11221875
J Immunol. 1999 Aug 15;163(4):1943-50
10438930
Blood. 2002 Jul 1;100(1):11-6
12070001
J Leukoc Biol. 2000 Nov;68(5):748-56
11073116
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61
9636188
Immunol Rev. 2006 Apr;210:52-66
16623764
Autoimmun Rev. 2008 May;7(5):384-90
18486926
J Autoimmun. 2008 Nov;31(3):197-200
18502096
Nat Immunol. 2006 Nov;7(11):1217-24
17013389
Blood. 2005 Jul 1;106(1):338-44
15769894
J Exp Med. 1998 Jan 5;187(1):1-14
9419206
J Autoimmun. 2008 Feb-Mar;30(1-2):5-11
18194728
J Exp Med. 2005 Dec 19;202(12):1627-33
16365146
J Autoimmun. 2007 Dec;29(4):295-302
17826951
PLoS Biol. 2005 Apr;3(4):e113
15799695
J Immunol. 2007 Dec 1;179(11):7376-84
18025181
J Immunol. 1999 May 1;162(9):5094-8
10227978
J Autoimmun. 2008 Feb-Mar;30(1-2):1-4
18191539
Int Immunol. 2000 Jun;12(6):909-14
10837418
J Exp Med. 2004 Nov 15;200(10):1325-35
15545356
J Exp Med. 2000 Feb 21;191(4):661-8
10684858
Expert Opin Biol Ther. 2007 Nov;7(11):1705-21
17961093
J Exp Med. 2005 Nov 7;202(9):1279-88
16275765
Immunol Rev. 2006 Dec;214:56-72
17100876
Hepatology. 2004 May;39(5):1321-31
15122761
Immunol Rev. 2000 Apr;174:63-76
10807507
J Autoimmun. 2008 Feb-Mar;30(1-2):99-103
18194729
J Exp Med. 2005 Aug 15;202(4):485-92
16087715
Arthritis Res Ther. 2007;9(6):R125
18053164
J Autoimmun. 2008 Feb-Mar;30(1-2):68-73
18191542
J Immunol. 1994 Jul 1;153(1):333-42
8207246
Cell Immunol. 2001 Dec 15;214(2):194-200
12088418
Hum Immunol. 2008 Aug;69(8):490-500
18619507
Nat Immunol. 2000 Dec;1(6):515-20
11101874
Blood. 2001 Apr 1;97(7):2067-74
11264173
Immunity. 2007 Jun;26(6):798-811
17540585
Curr Opin Immunol. 2004 Apr;16(2):167-73
15023409
J Autoimmun. 2008 Sep;31(2):188-95
18710796
Adv Immunol. 2009;102:1-94
19477319
Nat Rev Immunol. 2001 Oct;1(1):41-9
11905813
Hepatology. 2007 Jan;45(1):22-30
17187419
Nat Immunol. 2004 Dec;5(12):1260-5
15531883
J Autoimmun. 2007 Dec;29(4):310-8
17959357
J Immunol. 2003 Feb 1;170(3):1197-201
12538676
J Leukoc Biol. 2002 Oct;72(4):668-76
12377935
J Immunol. 2001 Jun 1;166(11):6578-84
11359810
J Immunol. 2008 Mar 15;180(6):3627-35
18322166
J Immunol. 2007 Oct 15;179(8):5126-36
17911598
Immunol Rev. 2008 Apr;222:357-68
18364014
J Immunol. 1999 Nov 1;163(9):4647-50
10528160
J Immunol. 1998 Dec 1;161(11):6014-21
9834083
J Exp Med. 1999 Apr 5;189(7):1121-8
10190903
J Immunol. 1985 Jun;134(6):4267-75
3989307
Annu Rev Immunol. 2009;27:147-63
19302037
Int Immunol. 2007 Mar;19(3):311-20
17289654
J Immunol. 2008 Nov 15;181(10):6779-88
18981095
Cancer Res. 2006 Nov 15;66(22):11005-12
17108139
J Exp Med. 2005 Jun 20;201(12):1973-85
15967825
Cancer Res. 2009 Apr 15;69(8):3563-9
19351841
Immunol Rev. 1997 Feb;155:145-54
9059890
J Immunol. 2002 Oct 15;169(8):4467-74
12370382
Science. 1997 Nov 28;278(5343):1626-9
9374463
J Immunol. 2005 Jul 15;175(2):693-9
16002664
Annu Rev Immunol. 2003;21:483-513
12543936
J Immunol. 2002 Nov 15;169(10):5377-81
12421908
J Clin Invest. 2007 Aug;117(8):2302-12
17641782
J Autoimmun. 2007 Dec;29(4):303-9
17888627
J Exp Med. 2002 Jul 1;196(1):119-27
12093876
Nat Med. 2001 Jan;7(1):94-100
11135622
Chem Soc Rev. 2006 Sep;35(9):771-9
16936925
J Exp Med. 2001 Mar 19;193(6):661-70
11257133